The safety and efficacy of intratumoral injection of DCs, generated from monocytes obtained by phlebotomy with GM-CSF and IL-4 in autologous plasma into the metastatic dermal or subcutaneous tumors of patients with melanoma and breast carcinoma, were examined in a pilot clinical study. The gene discussed is CSF2; the disease is melanoma.